Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 2450 of 3173 entries
View as:

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

Phase: N/A Priority: Normal
NCT ID: NCT02213263 Org: User:
Start: 09/30/14 End: 04/19/18 Due: 04/19/19

Glasdegib Renal Impairment Study

Phase: N/A Priority: Normal
NCT ID: NCT03596567 Org: User:
Start: 05/17/18 End: 09/19/18 Due: 09/19/19

First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01011296 Org: User:
Start: 12/31/09 End: 05/31/10 Due: 05/31/11

Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01149785 Org: User:
Start: 07/31/10 End: 09/30/10 Due: 09/30/11

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

Phase: N/A Priority: Normal
NCT ID: NCT03439514 Org: User:
Start: 04/17/18 End: 10/13/22 Due: 10/13/23

A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To

Phase: N/A Priority: Normal
NCT ID: NCT00232154 Org: User:
Start: 11/30/05 End: 06/30/06 Due: 06/30/07

A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks

Phase: N/A Priority: Normal
NCT ID: NCT00427401 Org: User:
Start: 02/28/07 End: 06/30/07 Due: 06/30/08

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01911273 Org: User:
Start: 10/31/13 End: 07/31/14 Due: 07/31/15

A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder

Phase: N/A Priority: Normal
NCT ID: NCT02216097 Org: User:
Start: 10/31/14 End: 03/31/15 Due: 03/31/16

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Phase: N/A Priority: Normal
NCT ID: NCT05394493 Org: User:
Start: 06/11/21 End: 08/30/23 Due: 08/30/24

Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

Phase: N/A Priority: Normal
NCT ID: NCT03842163 Org: User:
Start: 07/09/18 End: 06/08/22 Due: 06/08/23

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00615199 Org: User:
Start: 01/31/08 End: 10/31/09 Due: 10/31/10

Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01239745 Org: User:
Start: 04/30/11 End: 10/31/11 Due: 10/31/12

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

Phase: N/A Priority: Normal
NCT ID: NCT02531698 Org: User:
Start: 08/31/15 End: 03/31/17 Due: 03/31/18

Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02485769 Org: User:
Start: 06/30/15 End: 04/30/16 Due: 04/30/17

A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain

Phase: N/A Priority: Normal
NCT ID: NCT00657449 Org: User:
Start: 06/04/03 End: 10/05/04 Due: 10/05/05

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01925274 Org: User:
Start: 11/15/13 End: 04/06/16 Due: 04/06/17

A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan

Phase: N/A Priority: Normal
NCT ID: NCT00648258 Org: User:
Start: 07/31/03 End: 04/30/04 Due: 04/30/05

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

Phase: N/A Priority: Normal
NCT ID: NCT01543919 Org: User:
Start: 04/30/12 End: 09/30/13 Due: 09/30/14

Pharmacokinetics and Safety of RV521 Formulations

Phase: N/A Priority: Normal
NCT ID: NCT04065698 Org: User:
Start: 08/13/19 End: 09/09/19 Due: 09/09/20

Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02831855 Org: User:
Start: 09/01/16 End: 12/17/18 Due: 12/17/19

Ceftaroline China Pharmacokinetics Study

Phase: N/A Priority: Normal
NCT ID: NCT01458743 Org: User:
Start: 10/31/11 End: 04/30/12 Due: 04/30/13

Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532

Phase: N/A Priority: Normal
NCT ID: NCT01469481 Org: User:
Start: 11/30/11 End: 11/30/11 Due: 11/30/12

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00375674 Org: User:
Start: 08/01/07 End: 09/07/17 Due: 09/07/18

A Renal Impairment Study for PF-04965842

Phase: N/A Priority: Normal
NCT ID: NCT03660241 Org: User:
Start: 10/05/18 End: 11/05/19 Due: 11/05/20